Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Pharmacology and Therapeutics

Volumn 128, Issue 2, 2010, Pages 281-304

  Chiu, Chi Tso ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Apoptosis; Brain derived neurotrophic factor (BDNF); Glycogen synthase kinase 3 (GSK 3); Lithium; Neurodegenerative diseases; Neuroprotection

Indexed keywords

ANTICONVULSIVE AGENT; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE; CYTOCHROME C; DNA; GLUCOSE REGULATED PROTEIN 78; GLYCOGEN SYNTHASE KINASE 3; HEAT SHOCK PROTEIN 70; INOSITOL; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PROTEIN BAX; PROTEIN P53; SMAD3 PROTEIN; SMAD4 PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DEGENERATION; DEGENERATIVE DISEASE; DNA BINDING; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN STABILITY; RETINA DEGENERATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SPINOCEREBELLAR DEGENERATION; STROKE; TARDIVE DYSKINESIA; TRAUMATIC BRAIN INJURY; UPREGULATION;

ANIMALS; APOPTOSIS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LITHIUM; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 77957019846     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.07.006     Document Type: Review

References (474)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Aggarwal S.P., Zinman L., Simpson E., McKinley J., Jackson K.E., Pinto H., et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488.
3. Akassoglou K., Akpinar P., Murray S., Strickland S. Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice. Neurosci Lett 2003, 338:185-188.
4. Alessi D.R., Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998, 8:55-62.
5. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999, 453:260-264.
6. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002, 4:153-165.
7. American Psychiatric Association Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-50.
8. Aminoff M.J., Marshall J. Treatment of Huntington's chorea with lithium carbonate. A double-blind trial. Lancet 1974, 1:107-109.
9. Anden N.E., Dalen P., Johansson B. Baclofen and lithium in Huntington's chorea. Lancet 1973, 2:93.
10. Aoki T., Koike T., Nakano T., Shibahara K., Kondo S., Kikuchi H., et al. Induction of Bip mRNA upon programmed cell death of differentiated PC12 cells as well as rat sympathetic neurons. J Biochem 1997, 121:122-127.
11. Appleby B.S. Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets 2009, 8:353-362.
12. Asghari V., Wang J.F., Reiach J.S., Young L.T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 1998, 58:95-102.
13. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 2007, 7:904-912.
14. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27:370-377.
15. Bearden C.E., Thompson P.M., Dalwani M., Hayashi K.M., Lee A.D., Nicoletti M., et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007, 62:7-16.
16. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
17. Beaulieu J.M., Marion S., Rodriguiz R.M., Medvedev I.O., Sotnikova T.D., Ghisi V., et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008, 132:125-136.
18. Beaulieu J.M., Zhang X., Rodriguiz R.M., Sotnikova T.D., Cools M.J., Wetsel W.C., et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 2008, 105:1333-1338.
19. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
20. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004, 101:5099-5104.
21. Bedlack R.S., Maragakis N., Heiman-Patterson T. Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. Proc Natl Acad Sci U S A 2008, 105:E17.
22. Beere H.M., Wolf B.B., Cain K., Mosser D.D., Mahboubi A., Kuwana T., et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000, 2:469-475.
23. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006, 15:433-442.
24. Berger Z., Ttofi E.K., Michel C.H., Pasco M.Y., Tenant S., Rubinsztein D.C., et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet 2005, 14:3003-3011.
25. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59:411-419.
26. Berry-Kravis E., Sumis A., Hervey C., Nelson M., Porges S.W., Weng N., et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008, 29:293-302.
27. Beurel E., Michalek S.M., Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010, 31:24-31.
28. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004, 89:1313-1317.
29. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000, 97:11074-11079.
30. Bian Q., Shi T., Chuang D.M., Qian Y. Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res 2007, 1184:270-276.
31. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn Mouse, a model for Down syndrome. Brain Pathol 2009, 20:106-118.
32. Bijur G.N., De S.P., Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000, 275:7583-7590.
33. Bijur G.N., Jope R.S. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 2000, 75:2401-2408.
34. Boillee S., Vande V.C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
35. Boku S., Nakagawa S., Masuda T., Nishikawa H., Kato A., Kitaichi Y., et al. Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrus-derived neural precursor cells through GSK-3beta and beta-catenin/TCF pathway. Neuropsychopharmacology 2009, 34:805-815.
36. Bown C.D., Wang J.F., Young L.T. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 2000, 39:2162-2169.
37. Boyle W.J., Smeal T., Defize L.H., Angel P., Woodgett J.R., Karin M., et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991, 64:573-584.
38. Brambilla P., Stanley J.A., Nicoletti M.A., Sassi R.B., Mallinger A.G., Frank E., et al. 1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. J Affect Disord 2005, 86:61-67.
39. Brambilla P., Stanley J.A., Sassi R.B., Nicoletti M.A., Mallinger A.G., Keshavan M.S., et al. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 2004, 29:1918-1924.
40. Brinkman S.D., Pomara N., Barnett N., Block R., Domino E.F., Gershon S. Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia. Biol Psychiatry 1984, 19:157-164.
41. Brockington A., Wharton S.B., Fernando M., Gelsthorpe C.H., Baxter L., Ince P.G., et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006, 65:26-36.
42. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999, 59:427-468.
43. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
44. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001, 11:297-305.
45. Burk K., Globas C., Bosch S., Klockgether T., Zuhlke C., Daum I., et al. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J Neurol 2003, 250:207-211.
46. Caldero J., Brunet N., Tarabal O., Piedrafita L., Hereu M., Ayala V., et al. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 2010, 165:1353-1369.
47. Camins A., Crespo-Biel N., Junyent F., Verdaguer E., Canudas A.M., Pallas M. Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. Curr Drug Metab 2009, 10:433-447.
48. Camins A., Verdaguer E., Folch J., Canudas A.M., Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 2006, 19:453-460.
49. Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A.J., Caruso A., et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 2004, 24:6021-6027.
50. Carman J.S., Bigelow L.B., Wyatt R.J. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981, 42:124-128.
51. Carman J.S., Shoulson I., Chase T.N. Letter: Huntington's chorea treated with lithium carbonate. Lancet 1974, 1:811.
52. Carmichael J., Sugars K.L., Bao Y.P., Rubinsztein D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002, 277:33791-33798.
53. Centeno F., Mora A., Fuentes J.M., Soler G., Claro E. Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 1998, 9:4199-4203.
54. Chakraborty G., Saito M., Mao R.F., Wang R., Vadasz C., Saito M. Lithium blocks ethanol-induced modulation of protein kinases in the developing brain. Biochem Biophys Res Commun 2008, 367:597-602.
55. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999, 96:8745-8750.
56. Chang K., Barnea-Goraly N., Karchemskiy A., Simeonova D.I., Barnes P., Ketter T., et al. Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry 2005, 58:197-203.
57. Chang K., Karchemskiy A., Barnea-Goraly N., Garrett A., Simeonova D.I., Reiss A. Reduced amygdalar gray matter volume in familial pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005, 44:565-573.
58. Chang F., Steelman L.S., Shelton J.G., Lee J.T., Navolanic P.M., Blalock W.L., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 2003, 22:469-480.
59. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18:1162-1164.
60. Chen K.P., Shen W.W., Lu M.L. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci 2004, 58:25-29.
61. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999, 274:6039-6042.
62. Chen R.W., Qin Z.H., Ren M., Kanai H., Chalecka-Franaszek E., Leeds P., et al. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem 2003, 84:566-575.
63. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000, 75:1729-1734.
64. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999, 72:879-882.
65. Chen J., Zhang C., Jiang H., Li Y., Zhang L., Robin A., et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005, 25:281-290.
66. Chiu C.T., Liu G., Leeds P., Chuang D.M. A comparative behavioral study of the beneficial effects of mood stabilizing drugs lithium and valproate in transgenic mouse models of Huntington's disease. Program No. 240.23. The 39th Annual Meeting of Society for Neuroscience 2009.
67. Cho K.S., Chen D.F. Promoting optic nerve regeneration in adult mice with pharmaceutical approach. Neurochem Res 2008, 33:2126-2133.
68. Choi C.H., McBride S.M., Schoenfeld B.P., Liebelt D.A., Ferreiro D., Ferrick N.J., et al. Age-dependent cognitive impairment in a Drosophila Fragile X model and its pharmacological rescue. Biogerontology 2009, 11:347-362.
69. Chu B., Soncin F., Price B.D., Stevenson M.A., Calderwood S.K. Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J Biol Chem 1996, 271:30847-30857.
70. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
71. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005, 1053:195-204.
72. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002, 4:129-136.
73. Chuang D.M., Hough C., Senatorov V.V. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2005, 45:269-290.
74. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009, 32:591-601.
75. Chuang D.M., Manji H.K. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?. Biol Psychiatry 2007, 62:4-6.
76. Chuang D.M., Priller J. Potential use of lithium in neurodegenerative disorders. Lithium in Neuropsychiatry: The Comprehensive Guide 2006, 381-397. Informa Health Care, Abingdon, Oxfordshire, United Kingdom. M. Bauer, P. Grof, B. Müller-Oerlinghausen (Eds.).
77. Citrome L., Goldberg J.F., Stahl S.M. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005, 13:28-42.
78. Coffey C.E., Ross D.R., Ferren E.L., Sullivan J.L., Olanow C.W. Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate. Ann Neurol 1982, 12:375-379.
79. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001, 24:519-550.
80. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
81. Crawford D.C., Meadows K.L., Newman J.L., Taft L.F., Scott E., Leslie M., et al. Prevalence of the fragileXsyndrome in African-Americans. Am J Med Genet 2002, 110:226-233.
82. Crespo-Biel N., Camins A., Pallas M., Canudas A.M. Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 2009, 56:422-428.
83. Cruz J.C., Tsai L.H. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 2004, 14:390-394.
84. Cuervo A.M. Autophagy: many paths to the same end. Mol Cell Biochem 2004, 263:55-72.
85. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
86. Culmsee C., Zhu X., Yu Q.S., Chan S.L., Camandola S., Guo Z., et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001, 77:220-228.
87. Cuzzocrea S., Mazzon E., Di P.R., Muia C., Crisafulli C., Dugo L., et al. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006, 120:57-67.
88. Dalen P. Lithium therapy in Huntington's chorea and tardive dyskinesia. Lancet 1973, 1:107-108.
89. De Ferrari G.V., Chacon M.A., Barria M.I., Garrido J.L., Godoy J.A., Olivares G., et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 2003, 8:195-208.
90. De Sarno P., Axtell R.C., Raman C., Roth K.A., Alessi D.R., Jope R.S. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008, 181:338-345.
91. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164.
92. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2010, (Published online: May 25, 2010). 10.1016/j.pathophys.2010.04.004.
93. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
94. Dhariwala F.A., Rajadhyaksha M.S. An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 2008, 28:351-369.
95. Dill J., Wang H., Zhou F., Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 2008, 28:8914-8928.
96. D'Mello S.R., Anelli R., Calissano P. Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons. Exp Cell Res 1994, 211:332-338.
97. Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 2008, 8:425-436.
98. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., et al. Correction of fragileXsyndrome in mice. Neuron 2007, 56:955-962.
99. Dou H., Ellison B., Bradley J., Kasiyanov A., Poluektova L.Y., Xiong H., et al. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 2005, 25:8375-8385.
100. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001, 11:240-249.
101. Du W.J., Li J.K., Wang Q.Y., Hou J.B., Yu B. Lithium chloride preconditioning optimizes skeletal myoblast functions for cellular cardiomyoplasty in vitro via glycogen synthase kinase-3beta/beta-catenin signaling. Cells Tissues Organs 2009, 190:11-19.
102. Duan W., Zhu X., Ladenheim B., Yu Q.S., Guo Z., Oyler J., et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002, 52:597-606.
103. Dugo L., Collin M., Allen D.A., Patel N.S., Bauer I., Mervaala E.M., et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005, 33:1903-1912.
104. Duka T., Duka V., Joyce J.N., Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009, 23:2820-2830.
105. Ekshyyan O., Aw T.Y. Apoptosis in acute and chronic neurological disorders. Front Biosci 2004, 9:1567-1576.
106. Eskandari F., Mistry S., Martinez P.E., Torvik S., Kotila C., Sebring N., et al. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism 2005, 54:918-924.
107. Everall I.P., Bell C., Mallory M., Langford D., Adame A., Rockestein E., et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 2002, 21:493-501.
108. Fan Y., Yang G.Y. Therapeutic angiogenesis for brain ischemia: a brief review. J Neuroimmune Pharmacol 2007, 2:284-289.
109. Feinstein D.L., Galea E., Aquino D.A., Li G.C., Xu H., Reis D.J. Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. J Biol Chem 1996, 271:17724-17732.
110. Feng Y.T. The necessity for a collection development policy statement. Libr Resour Tech Serv 1979, 23:39-44.
111. Feng H.L., Leng Y., Ma C.H., Zhang J., Ren M., Chuang D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008, 155:567-572.
112. Ferguson S.S., Downey W.E., Colapietro A.M., Barak L.S., Menard L., Caron M.G. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996, 271:363-366.
113. Ferrucci M., Spalloni A., Bartalucci A., Cantafora E., Fulceri F., Nutini M., et al. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis 2010, 37:370-383.
114. Fink A.L. Chaperone-mediated protein folding. Physiol Rev 1999, 79:425-449.
115. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 2000, 25:11-14.
116. Fisher S.K., Agranoff B.W., Quiroz J.A., Gould T.D., Manji H.K. Receptor activation and inositol lipid hydrolysis in neural tissues: molecular effects of lithium. J Neurochem 1987, 48:999-1017.
117. Foerster K., Regli F. Lithium therapy of extrapyramidal movement disorders-an attempt (author's transl). Nervenarzt 1977, 48:228-232.
118. Fornai F., Ferrucci M., Gesi M., Bandettini di P.A., Giorgi F.S., Biagioni F., et al. A hypothesis on prion disorders: are infectious, inherited, and sporadic causes so distinct?. Brain Res Bull 2006, 69:95-100.
119. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008, 105:2052-2057.
120. Foster A.C., Collins J.F., Schwarcz R. On the excitotoxic properties of quinolinic acid, 2, 3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 1983, 22:1331-1342.
121. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
122. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003, 348:1365-1375.
123. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001, 158:100-106.
124. Fukunaga K., Ishigami T., Kawano T. Transcriptional regulation of neuronal genes and its effect on neural functions: expression and function of forkhead transcription factors in neurons. J Pharmacol Sci 2005, 98:205-211.
125. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J Neurosci 2002, 22:4842-4849.
126. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
127. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004, 27:107-144.
128. Gallicchio V.S., Cibull M.L., Hughes N.K., Tse K.F. Effect of lithium in murine immunodeficiency virus infected animals. Pathobiology 1993, 61:216-221.
129. Gao X.M., Fukamauchi F., Chuang D.M. Long-term biphasic effects of lithium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochem Int 1993, 22:395-403.
130. Gao T., Newton A.C. The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem 2002, 277:31585-31592.
131. Garber K., Smith K.T., Reines D., Warren S.T. Transcription, translation and fragileXsyndrome. Curr Opin Genet Dev 2006, 16:270-275.
132. Garcia C.A., Benakanakere M.R., Alard P., Kosiewicz M.M., Kinane D.F., Martin M. Antigenic experience dictates functional role of glycogen synthase kinase-3 in human CD4+ T cell responses. J Immunol 2008, 181:8363-8371.
133. Gatchel J.R., Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005, 6:743-755.
134. Gerlach J., Thorsen K., Munkvad I. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. Pharmakopsychiatr Neuropsychopharmakol 1975, 8:51-56.
135. Ghribi O., Herman M.M., Savory J. Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J Neurosci Res 2003, 71:853-862.
136. Gill A., Kidd J., Vieira F., Thompson K., Perrin S. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009, 4:e6489.
137. Gomes F.C., Sousa V.O., Romao L. Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci 2005, 23:413-424.
138. Goni-Oliver P., Lucas J.J., Avila J., Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 2007, 282:22406-22413.
139. Goodwin F.K. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 2003, 64(Suppl 5):18-24.
140. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
141. Gould T.D., Chen G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.
142. Gould T.D., Einat H., Bhat R., Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004, 7:387-390.
143. Gould T.D., Einat H., O'Donnell K.C., Picchini A.M., Schloesser R.J., Manji H.K. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 2007, 32:2173-2183.
144. Gould T.D., Gray N.A., Manji H.K. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 2003, 48:49-53.
145. Gould T.D., O'Donnell K.C., Picchini A.M., Dow E.R., Chen G., Manji H.K. Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res 2008, 189:117-125.
146. Gould T.D., Quiroz J.A., Singh J., Zarate C.A., Manji H.K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004, 9:734-755.
147. Grandjean E.M., Aubry J.M. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009, 23:331-349.
148. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
149. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
150. Guo S., Arai K., Stins M.F., Chuang D.M., Lo E.H. Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 2009, 40:652-655.
151. Hafler D.A. Multiple sclerosis. J Clin Invest 2004, 113:788-794.
152. Hagerman R.J., Ono M.Y., Hagerman P.J. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry 2005, 18:490-496.
153. Hampel H., Ewers M., Burger K., Annas P., Mortberg A., Bogstedt A., et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009, 70:922-931.
154. Han R., Gao B., Sheng R., Zhang L.S., Zhang H.L., Gu Z.L., et al. Synergistic effects of prostaglandin E1 and lithium in a rat model of cerebral ischemia. Acta Pharmacol Sin 2008, 29:1141-1149.
155. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
156. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858.
157. Hashimoto R., Fujimaki K., Jeong M.R., Christ L., Chuang D.M. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-d-aspartate receptor-mediated excitotoxicity. FEBS Lett 2003, 538:145-148.
158. Hashimoto R., Senatorov V., Kanai H., Leeds P., Chuang D.M. Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 2003, 117:55-61.
159. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002, 80:589-597.
160. Hashimoto R., Takei N., Shimazu K., Christ L., Lu B., Chuang D.M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002, 43:1173-1179.
161. He H., Lam M., McCormick T.S., Distelhorst C.W. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J Cell Biol 1997, 138:1219-1228.
162. He H., McColl K., Distelhorst C.W. Involvement of c-Fos in signaling grp78 induction following ER calcium release. Oncogene 2000, 19:5936-5943.
163. Heine V.M., Zareno J., Maslam S., Joels M., Lucassen P.J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 2005, 21:1304-1314.
164. Heiseke A., Aguib Y., Riemer C., Baier M., Schatzl H.M. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem 2009, 109:25-34.
165. Hendrick J.P., Hartl F.U. Molecular chaperone functions of heat-shock proteins. Annu Rev Biochem 1993, 62:349-384.
166. Hickey M.A., Chesselet M.F. Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:255-265.
167. Higgins P.J. The TGF-beta1/upstream stimulatory factor-regulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer's disease. J Biomed Biotechnol 2006, 2006:15792.
168. Hiroi T., Wei H., Hough C., Leeds P., Chuang D.M. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J 2005, 5:102-111.
169. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15:965-977.
170. Hoehn B., Ringer T.M., Xu L., Giffard R.G., Sapolsky R.M., Steinberg G.K., et al. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 2001, 21:1303-1309.
171. Holroyd S., Smith D. Disabling parkinsonism due to lithium: a case report. J Geriatr Psychiatry Neurol 1995, 8:118-119.
172. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997, 272:25326-25332.
173. Hongisto V., Smeds N., Brecht S., Herdegen T., Courtney M.J., Coffey E.T. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 2003, 23:6027-6036.
174. Hou X.Y., Zhang G.Y., Yan J.Z., Chen M., Liu Y. Activation of NMDA receptors and L-type voltage-gated calcium channels mediates enhanced formation of Fyn-PSD95-NR2A complex after transient brain ischemia. Brain Res 2002, 955:123-132.
175. Hough C., Lu S.J., Davis C.L., Chuang D.M., Post R.M. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 1999, 46:247-255.
176. Huang W., Galdzicki Z., van G.P., Balbo A., Chikhale E.G., Schapiro M.B., et al. Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment. Neuroreport 2000, 11:445-448.
177. Huang H.C., Klein P.S. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr Drug Targets 2006, 7:1389-1397.
178. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003, 72:609-642.
179. Huang X., Wu D.Y., Chen G., Manji H., Chen D.F. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci 2003, 44:347-354.
180. Huelsken J., Behrens J. The Wnt signalling pathway. J Cell Sci 2002, 115:3977-3978.
181. Inestrosa N.C., Alvarez A., Godoy J., Reyes A., De Ferrari G.V. Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 2000, 176:53-59.
182. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
183. Jacobsen J.P., Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004, 1024:183-192.
184. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 2002, 99:11946-11950.
185. Johannessen L.C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
186. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999, 4:117-128.
187. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999, 4:21-25.
188. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003, 24:441-443.
189. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
190. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
191. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007, 32:577-595.
192. Jorda E.G., Verdaguer E., Canudas A.M., Jimenez A., Garcia de A.S., Allgaier C., et al. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 2005, 134:1001-1011.
193. Jorda E.G., Verdaguer E., Morano A., Jimenez A., Canudas A.M., Camins A., et al. Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disord 2004, 6:144-149.
194. Jus A., Villeneuve A., Gautier J., Jus K., Villeneuve C., Pires P., et al. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978, 4:140-149.
195. Kaga S., Zhan L., Altaf E., Maulik N. Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 2006, 40:138-147.
196. Kaidanovich-Beilin O., Lipina T.V., Takao K., van E.M., Hattori S., Laliberte C., et al. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2009, 2:35.
197. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004, 55:781-784.
198. Kalasapudi V.D., Sheftel G., Divish M.M., Papolos D.F., Lachman H.M. Lithium augments fos protoonocogene expression in PC12 pheochromocytoma cells: implications for therapeutic action of lithium. Brain Res 1990, 521:47-54.
199. Karcher D., Chamoles N., Zeman W., Lowenthal A. Hydrosoluble proteins of the nervous system of man and the animal. Acta Zool Pathol Antverp 1969, 48:73-76.
200. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann N Y Acad Sci 1998, 851:139-146.
201. Katayama T., Imaizumi K., Sato N., Miyoshi K., Kudo T., Hitomi J., et al. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol 1999, 1:479-485.
202. Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999, 13:1211-1233.
203. Kellams J.J., Small J.G., Milstein V., Perex H.C. Lithium combined with neuroleptics in the treatment of chronic schizophrenia. Psychopharmacol Bull 1976, 12:27-30.
204. Kessing L.V., Sondergard L., Forman J.L., Andersen P.K. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008, 65:1331-1335.
205. Ketter T.A., Manji H.K., Post R.M. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003, 23:484-495.
206. Kim Y.R., van Meer M.P., Tejima E., Murata Y., Mandeville J.B., Dai G., et al. Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke 2008, 39:439-447.
207. King T.D., Bijur G.N., Jope R.S. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 2001, 919:106-114.
208. Kirshenboim N., Plotkin B., Shlomo S.B., Kaidanovich-Beilin O., Eldar-Finkelman H. Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosci 2004, 24:237-245.
209. Kitagawa K., Matsumoto M., Tsujimoto Y., Ohtsuki T., Kuwabara K., Matsushita K., et al. Amelioration of hippocampal neuronal damage after global ischemia by neuronal overexpression of BCL-2 in transgenic mice. Stroke 1998, 29:2616-2621.
210. Klawans H.L., Weiner W.J., Nausieda P.A. The effect of lithium on an animal model of tardive dyskinesia. Prog Neuropsychopharmacol 1977, 1:53-60.
211. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996, 93:8455-8459.
212. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
213. Koh S.H., Song C., Noh M.Y., Kim H.Y., Lee K.Y., Lee Y.J., et al. Inhibition of glycogen synthase kinase-3 reduces l-DOPA-induced neurotoxicity. Toxicology 2008, 247:112-118.
214. Kopnisky K.L., Chalecka-Franaszek E., Gonzalez-Zulueta M., Chuang D.M. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 2003, 116:425-435.
215. Kozlovsky N., Nadri C., Agam G. Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 2005, 15:1-11.
216. Kramer M., Dang J., Baertling F., Denecke B., Clarner T., Kirsch C., et al. TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analyses. J Neurosci Methods 2010, 187:84-89.
217. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
218. Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W., Amaravadi L., et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238:301-313.
219. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., Nicholson L.B. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002, 20:101-123.
220. Kumar A., Zloza A., Moon R.T., Watts J., Tenorio A.R., Al-Harthi L. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol 2008, 82:2813-2820.
221. Kutcher M.E., Klagsbrun M., Mamluk R. VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during development. FASEB J 2004, 18:1952-1954.
222. Lam R.W., Allain S., Sullivan K., Beattie C.W., Remick R.A., Zis A.P. Effects of chronic lithium treatment on retinal electrophysiologic function. Biol Psychiatry 1997, 41:737-742.
223. Lam M., Dubyak G., Chen L., Nunez G., Miesfeld R.L., Distelhorst C.W. Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci U S A 1994, 91:6569-6573.
224. Lambert S.L., Martinez O.M. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007, 179:8225-8234.
225. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
226. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
227. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008, 28:2576-2588.
228. Leonard D.P., Kidson M.A., Brown J.G., Shannon P.J., Taryan S. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry 1975, 9:115-118.
229. Leonard D.P., Kidson M.A., Shannon P.J., Brown J. Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea. Lancet 1974, 2:1208-1209.
230. Leroy K., Ando K., Heraud C., Yilmaz Z., Authelet M., Boeynaems J.M., et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010, 19:705-719.
231. Letendre S.L., Woods S.P., Ellis R.J., Atkinson J.H., Masliah E., van den Brande G., et al. Lithium improves HIV-associated neurocognitive impairment. AIDS 2006, 20:1885-1888.
232. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
233. Leyhe T., Eschweiler G.W., Stransky E., Gasser T., Annas P., Basun H., et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009, 16:649-656.
234. Li X., Ketter T.A., Frye M.A. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?. J Affect Disord 2002, 69:1-14.
235. Liang M.H., Chuang D.M. Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 2006, 281:30479-30484.
236. Liang M.H., Chuang D.M. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 2007, 282:3904-3917.
237. Liang M.H., Wendland J.R., Chuang D.M. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci 2008, 37:440-453.
238. Lieberman A., Gopinathan G. Treatment of "on-off" phenomena with lithium. Ann Neurol 1982, 12:402.
239. Lin D., Mok H., Yatham L.N. Polytherapy in bipolar disorder. CNS Drugs 2006, 20:29-42.
240. Lindquist S. The heat-shock response. Annu Rev Biochem 1986, 55:1151-1191.
241. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
242. Liu Z.H., Chuang D.M., Smith C.B. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int. J. Neuropsychopharmacol. 2010, doi:10.1017/S1461145710000520 (Published online: May 25, 2010).
243. Liu F., Gong X., Zhang G., Marquis K., Reinhart P., Andree T.H. The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem 2005, 95:1363-1372.
244. Liu Z.H., Smith C.B. Dissociation of social and nonsocial anxiety in a mouse model of fragileXsyndrome. Neurosci Lett 2009, 454:62-66.
245. Liu H., Thurig S., Mohamed O., Dufort D., Wallace V.A. Mapping canonical Wnt signaling in the developing and adult retina. Invest Ophthalmol Vis Sci 2006, 47:5088-5097.
246. Liu H., Xu S., Wang Y., Mazerolle C., Thurig S., Coles B.L., et al. Ciliary margin transdifferentiation from neural retina is controlled by canonical Wnt signaling. Dev Biol 2007, 308:54-67.
247. Liu Y., Zhang G., Gao C., Hou X. NMDA receptor activation results in tyrosine phosphorylation of NMDA receptor subunit 2A(NR2A) and interaction of Pyk2 and Src with NR2A after transient cerebral ischemia and reperfusion. Brain Res 2001, 909:51-58.
248. Lohse M.J., Lefkowitz R.J., Caron M.G., Benovic J.L. Inhibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors. Proc Natl Acad Sci U S A 1989, 86:3011-3015.
249. Ma Y., Hendershot L.M. The unfolding tale of the unfolded protein response. Cell 2001, 107:827-830.
250. Ma J., Zhang G.Y. Lithium reduced N-methyl-d-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci Lett 2003, 348:185-189.
251. Ma J., Zhang G.Y., Liu Y., Yan J.Z., Hao Z.B. Lithium suppressed Tyr-402 phosphorylation of proline-rich tyrosine kinase (Pyk2) and interactions of Pyk2 and PSD-95 with NR2A in rat hippocampus following cerebral ischemia. Neurosci Res 2004, 49:357-362.
252. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
253. Macdonald A., Briggs K., Poppe M., Higgins A., Velayudhan L., Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008, 23:704-711.
254. Maggirwar S.B., Tong N., Ramirez S., Gelbard H.A., Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999, 73:578-586.
255. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8:741-752.
256. Majda B.T., Meloni B.P., Rixon N., Knuckey N.W. Suppression subtraction hybridization and northern analysis reveal upregulation of heat shock, trkB, and sodium calcium exchanger genes following global cerebral ischemia in the rat. Brain Res Mol Brain Res 2001, 93:173-179.
257. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7:541-547.
258. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35:5-49.
259. Manji H.K., Lenox R.H. Lithium: a molecular transducer of mood-stabilization in the treatment of bipolar disorder. Neuropsychopharmacology 1998, 19:161-166.
260. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray A., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707-742.
261. Manyam N.V., Bravo-Fernandez E. Lithium carbonate in Huntington's chorea. Lancet 1973, 1:1010.
262. Mao Z., Liu L., Zhang R., Li X. Lithium reduces FoxO3a transcriptional activity by decreasing its intracellular content. Biol Psychiatry 2007, 62:1423-1430.
263. Marmol F. Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1761-1771.
264. Martin J.B., Gusella J.F. Huntington's disease. Pathogenesis and management. N Engl J Med 1986, 315:1267-1276.
265. Martin L., Magnaudeix A., Esclaire F., Yardin C., Terro F. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 2009, 1252:66-75.
266. Martinez R.P., Raffa R.B. LiCl attenuates M(1)AChR-mediated intrathecal pilocarpine-induced reciprocal hindlimb scratching in mice. Pharmacology 2002, 65:210-214.
267. Mattson M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal 2006, 8:1997-2006.
268. Mattson M.P., Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 2003, 9:196-205.
269. Mattson M.P., LaFerla F.M., Chan S.L., Leissring M.A., Shepel P.N., Geiger J.D. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000, 23:222-229.
270. Mattsson B. Huntington's chorea and lithium therapy. Lancet 1973, 1:718-719.
271. Maurer M.H., Tripps W.K., Feldmann R.E., Kuschinsky W. Expression of vascular endothelial growth factor and its receptors in rat neural stem cells. Neurosci Lett 2003, 344:165-168.
272. Mazlo M., Pataky I., Szucs R. Morphological study of the kidneys of lithium treated rats. Acta Morphol Hung 1983, 31:309-314.
273. McBride S.M., Choi C.H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragileXsyndrome. Neuron 2005, 45:753-764.
274. McCaul J.A., Stern G.M. Letter: Lithium in Parkinson's disease. Lancet 1974, 1:1117.
275. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007, 8:913-919.
276. Meijer L., Flajolet M., Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004, 25:471-480.
277. Meininger V., Shefner J., Cudkowicz M. Lithium therapy in ALS. Amyotroph Lateral Scler 2008, 9:122.
278. Melchor J.P., Pawlak R., Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003, 23:8867-8871.
279. Melendez A., Neufeld T.P. The cell biology of autophagy in metazoans: a developing story. Development 2008, 135:2347-2360.
280. Mendes C.T., Mury F.B., de Sa M.E., Alberto F.L., Forlenza O.V., Dias-Neto E., et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci 2009, 259:16-22.
281. Meng H., Zhang Z., Zhang R., Liu X., Wang L., Robin A.M., et al. Biphasic effects of exogenous VEGF on VEGF expression of adult neural progenitors. Neurosci Lett 2006, 393:97-101.
282. Mielke K., Herdegen T. JNK and p38 stresskinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000, 61:45-60.
283. Min W.W., Yuskaitis C.J., Yan Q., Sikorski C., Chen S., Jope R.S., et al. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009, 56:463-472.
284. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol. Psychiatry 2000, 48:1-8.
285. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., Manji H.K. Lithium-induced increase in human brain grey matter. Lancet 2000, 356:1241-1242.
286. Morabito M.A., Sheng M., Tsai L.H. Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J Neurosci 2004, 24:865-876.
287. Moscovich D.G. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993, 163:410-412.
288. Mosser D.D., Caron A.W., Bourget L., Meriin A.B., Sherman M.Y., Morimoto R.I., et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000, 20:7146-7159.
289. Mudher A., Shepherd D., Newman T.A., Mildren P., Jukes J.P., Squire A., et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004, 9:522-530.
290. Mummery R.V. Letter: Caries under composite restorations. Br Dent J 1975, 139:263.
291. Munoz-Montano J.R., Lim F., Moreno F.J., Avila J., Diaz-Nido J. Glycogen synthase kinase-3 modulates neurite outgrowth in cultured neurons: possible implications for neurite pathology in Alzheimer's disease. J Alzheimers Dis 1999, 1:361-378.
292. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 1997, 411:183-188.
293. Nakashima H., Ishihara T., Suguimoto P., Yokota O., Oshima E., Kugo A., et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 2005, 110:547-556.
294. Neri L.M., Borgatti P., Capitani S., Martelli A.M. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta 2002, 1584:73-80.
295. Nguyen K.C., Rosales J.L., Barboza M., Lee K.Y. Controversies over p25 in Alzheimer's disease. J Alzheimers Dis 2002, 4:123-126.
296. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395.
297. Nixon R.A. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 2005, 26:373-382.
298. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005, 102:6990-6995.
299. Nocjar C., Hammonds M.D., Shim S.S. Chronic lithium treatment magnifies learning in rats. Neuroscience 2007, 150:774-788.
300. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998, 9:2081-2084.
301. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998, 95:2642-2647.
302. Nonaka S., Katsube N., Chuang D.M. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 1998, 286:539-547.
303. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
304. Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007, 190:359-360.
305. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004, 24:6791-6798.
306. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hochman A., Gorodin S., et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A 1998, 95:5789-5794.
307. Omata, N., Chiu, C. T., Moya, P. R., Leng, Y., Wang, Z., Hunsberger, J. G., et al. (2010). Lentiviral-mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol. (Published online: July 07, 2010). doi:10.1017/S1461145710000726.
308. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997, 69:2336-2344.
309. Pardo R., Andreolotti A.G., Ramos B., Picatoste F., Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 2003, 87:417-426.
310. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
311. Pawlak R., Magarinos A.M., Melchor J., McEwen B., Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 2003, 6:168-174.
312. Perez M., Hernandez F., Lim F., Diaz-Nido J., Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003, 5:301-308.
313. Perez M., Rojo A.I., Wandosell F., Diaz-Nido J., Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J 2003, 372:129-136.
314. Pert A., Rosenblatt J.E., Sivit C., Pert C.B., Bunney W.E. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978, 201:171-173.
315. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001, 41:789-813.
316. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
317. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
318. Pickar D., Davies R.K. Tardive dyskinesia in younger patients. Am J Psychiatry 1978, 135:385-386.
319. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in fragileXsyndrome. Cell 1991, 66:817-822.
320. Pizzasegola C., Caron I., Daleno C., Ronchi A., Minoia C., Carri M.T., et al. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009, 10:221-228.
321. Planel E., Yasutake K., Fujita S.C., Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001, 276:34298-34306.
322. Polter A., Beurel E., Yang S., Garner R., Song L., Miller C.A., et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
323. Polter A., Yang S., Zmijewska A.A., van G.T., Paik J.H., Depinho R.A., et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009, 65:150-159.
324. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
325. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van C.H., Goris I., et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006, 26:9022-9029.
326. Prusiner S.B. Prions. Proc Natl Acad Sci U S A 1998, 95:13363-13383.
327. Qin M., Kang J., Smith C.B. Increased rates of cerebral glucose metabolism in a mouse model of fragileXmental retardation. Proc Natl Acad Sci U S A 2002, 99:15758-15763.
328. Quiroz J.A., Gould T.D., Manji H.K. Molecular effects of lithium. Mol Interv 2004, 4:259-272.
329. Rajdev S., Hara K., Kokubo Y., Mestril R., Dillmann W., Weinstein P.R., et al. Mice overexpressing rat heat shock protein 70 are protected against cerebral infarction. Ann Neurol 2000, 47:782-791.
330. Rametti A., Esclaire F., Yardin C., Cogne N., Terro F. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection. Neurosci Lett 2008, 434:93-98.
331. Rametti A., Esclaire F., Yardin C., Terro F. Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 2004, 279:54518-54528.
332. Ravagnan L., Gurbuxani S., Susin S.A., Maisse C., Daugas E., Zamzami N., et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001, 3:839-843.
333. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107-1117.
334. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36:585-595.
335. Reda F.A., Escobar J.I., Scanlan J.M. Lithium carbonate in the treatment of tardive dyskinesia. Am J Psychiatry 1975, 132:560-562.
336. Ren M., Senatorov V.V., Chen R.W., Chuang D.M. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 2003, 100:6210-6215.
337. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007, 27:1981-1991.
338. Roh M.S., Eom T.Y., Zmijewska A.A., De S.P., Roth K.A., Jope R.S. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry 2005, 57:278-286.
339. Rohn T.T., Vyas V., Hernandez-Estrada T., Nichol K.E., Christie L.A., Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 2008, 28:3051-3059.
340. Rosa A.O., Kaster M.P., Binfare R.W., Morales S., Martin-Aparicio E., Navarro-Rico M.L., et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1549-1556.
341. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
342. Rosenbaum A.H., Niven R.G., Hanson N.P., Swanson D.W. Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv Syst 1977, 38:423-427.
343. Ross D.R., Coffey C.E., Ferren E.L., Walker J.I., Olanow C.W. "On-off" syndrome treated with lithium carbonate: a case report. Am J Psychiatry 1981, 138:1626-1627.
344. Rossi C., Angelucci A., Costantin L., Braschi C., Mazzantini M., Babbini F., et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci 2006, 24:1850-1856.
345. Rowe M.K., Chuang D.M. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 2004, 6:1-18.
346. Rowe M.K., Wiest C., Chuang D.M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007, 31:920-931.
347. Rowland L.P. Amyotrophic lateral sclerosis. Curr Opin Neurol 1994, 7:310-315.
348. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet 2002, 18:202-209.
349. Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007, 6:304-312.
350. Ryves W.J., Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001, 280:720-725.
351. Samson A.L., Medcalf R.L. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006, 50:673-678.
352. Sang H., Lu Z., Li Y., Ru B., Wang W., Chen J. Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett 2001, 312:141-144.
353. Sanyal S., Kim S.M., Ramaswami M. Retrograde regulation in the CNS; neuron-specific interpretations of TGF-beta signaling. Neuron 2004, 41:845-848.
354. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005, 170:1101-1111.
355. Sarkar S., Krishna G., Imarisio S., Saiki S., O'Kane C.J., Rubinsztein D.C. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008, 17:170-178.
356. Sarkar S., Rubinsztein D.C. Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy 2006, 2:132-134.
357. Sassi R.B., Brambilla P., Hatch J.P., Nicoletti M.A., Mallinger A.G., Frank E., et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry 2004, 56:467-475.
358. Scali C., Caraci F., Gianfriddo M., Diodato E., Roncarati R., Pollio G., et al. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis 2006, 24:254-265.
359. Schenk G., Leijnse-Ybema H.J. Letter: Huntington's chorea and levodopa. Lancet 1974, 1:364.
360. Schifitto G., Zhong J., Gill D., Peterson D.R., Gaugh M.D., Zhu T., et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009, 15:176-186.
361. Schuettauf F., Rejdak R., Thaler S., Bolz S., Lehaci C., Mankowska A., et al. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp Eye Res 2006, 83:1128-1134.
362. Schwarcz R., Whetsell W.O. Post-mortem high affinity glutamate uptake in human brain. Neuroscience 1982, 7:1771-1778.
363. Segal R.A., Greenberg M.E. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996, 19:463-489.
364. Seggie J. Lithium and the retina. Prog Neuropsychopharmacol Biol Psychiatry 1988, 12:241-253.
365. Seidensticker M.J., Behrens J. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 2000, 1495:168-182.
366. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
367. Senatorov V.V., Ren M., Kanai H., Wei H., Chuang D.M. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 2004, 9:371-385.
368. Shacka J.J., Roth K.A. Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 2005, 4:25-39.
369. Shao L., Sun X., Xu L., Young L.T., Wang J.F. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci 2006, 78:1317-1323.
370. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
371. Sherman W.R., Gish B.G., Honchar M.P., Munsell L.Y. Effects of lithium on phosphoinositide metabolism in vivo. Fed Proc 1986, 45:2639-2646.
372. Shibata M., Lu T., Furuya T., Degterev A., Mizushima N., Yoshimori T., et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem 2006, 281:14474-14485.
373. Shimizu T., Shibata M., Wakisaka S., Inoue T., Mashimo T., Yoshiya I. Intrathecal lithium reduces neuropathic pain responses in a rat model of peripheral neuropathy. Pain 2000, 85:59-64.
374. Shin J.H., Cho S.I., Lim H.R., Lee J.K., Lee Y.A., Noh J.S., et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 2007, 71:965-975.
375. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
376. Silva R., Martins L., Longatto-Filho A., Almeida O.F., Sousa N. Lithium prevents stress-induced reduction of vascular endothelium growth factor levels. Neurosci Lett 2007, 429:33-38.
377. Silva A.K., Yi H., Hayes S.H., Seigel G.M., Hackam A.S. Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway. Mol Vis 2010, 16:36-45.
378. Simpson G.M., Branchey M.H., Lee J.H., Voitashevsky A., Zoubok B. Lithium in tardive dyskinesia. Pharmakopsychiatr Neuropsychopharmakol 1976, 9:76-80.
379. Sinha D., Wang Z., Ruchalski K.L., Levine J.S., Krishnan S., Lieberthal W., et al. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am J Physiol Renal Physiol 2005, 288:F703-F713.
380. Small J.G., Kellams J.J., Milstein V., Moore J. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975, 132:1315-1317.
381. Soares-Weiser K.V., Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003, CD000208.
382. Son H., Yu I.T., Hwang S.J., Kim J.S., Lee S.H., Lee Y.S., et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 2003, 85:872-881.
383. Song L., De S.P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002, 277:44701-44708.
384. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
385. Speirs J., Hirsch S.R. Severe lithium toxicity with "normal" serum concentrations. Br Med J 1978, 1:815-816.
386. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragileXsyndrome. Genes Brain Behav 2005, 4:420-430.
387. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-945.
388. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668.
389. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
390. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005, 26:565-571.
391. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006, 60:12-21.
392. Su H., Chu T.H., Wu W. Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord. Exp Neurol 2007, 206:296-307.
393. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004, 43:6899-6908.
394. Su H., Zhang W., Guo J., Guo A., Yuan Q., Wu W. Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor. J Neurochem 2009, 108:1385-1398.
395. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19:233-238.
396. Sun X., Sato S., Murayama O., Murayama M., Park J.M., Yamaguchi H., et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002, 321:61-64.
397. Sztein M.B., Simon G.L., Parenti D.M., Scheib R., Goldstein A.L., Goodman R., et al. In vitro effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with AIDS-related complex. Clin Immunol Immunopathol 1987, 44:51-62.
398. Tabrizi P., Wang L., Seeds N., McComb J.G., Yamada S., Griffin J.H., et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999, 19:2801-2806.
399. Takagi N., Shinno K., Teves L., Bissoon N., Wallace M.C., Gurd J.W. Transient ischemia differentially increases tyrosine phosphorylation of NMDA receptor subunits 2A and 2B. J Neurochem 1997, 69:1060-1065.
400. Takahashi-Yanaga F., Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007, 104:293-302.
401. Takayama S., Reed J.C., Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003, 22:9041-9047.
402. Tanaka T., Zhong J., Iqbal K., Trenkner E., Grundke-Iqbal I. The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Lett 1998, 426:248-254.
403. Taylor-Robinson S.D., Weeks R.A., Bryant D.J., Sargentoni J., Marcus C.D., Harding A.E., et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996, 11:167-173.
404. Terao T., Nakano H., Inoue Y., Okamoto T., Nakamura J., Iwata N. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1125-1128.
405. The Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragileXmental retardation. Cell 1994, 78:23-33.
406. Tolosa L., Mir M., Asensio V.J., Olmos G., Llado J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 2008, 105:1080-1090.
407. Tondo L., Baldessarini R.J. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 2009, 18:179-183.
408. Tong N., Sanchez J.F., Maggirwar S.B., Ramirez S.H., Guo H., Dewhurst S., et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 2001, 13:1913-1922.
409. Trojanowski J.Q., Lee V.M. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J 1995, 9:1570-1576.
410. Tsai S.J. The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Med Hypotheses 2006, 66:319-322.
411. Tsuchiya D., Hong S., Matsumori Y., Shiina H., Kayama T., Swanson R.A., et al. Overexpression of rat heat shock protein 70 is associated with reduction of early mitochondrial cytochrome C release and subsequent DNA fragmentation after permanent focal ischemia. J Cereb Blood Flow Metab 2003, 23:718-727.
412. Tsuji S., Morinobu S., Tanaka K., Kawano K., Yamawaki S. Lithium, but not valproate, induces the serine/threonine phosphatase activity of protein phosphatase 2A in the rat brain, without affecting its expression. J Neural Transm 2003, 110:413-425.
413. van Harten P.N., Hoek H.W., Matroos G.E., van O.J. Evidence that lithium protects against tardive dyskinesia: the Curacao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol 2008, 18:152-155.
414. Van Woert M.H., Ambani L.M. Lithium and levodopa in parkinsonism. Lancet 1973, 1:1390-1391.
415. Vanacore N., Galeotti F. A clinical specification for a randomized clinical trial on lithium in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008, 105:E35.
416. Venkatachalam K., Long A.A., Elsaesser R., Nikolaeva D., Broadie K., Montell C. Motor deficit in a Drosophila model of mucolipidosis type IV due to defective clearance of apoptotic cells. Cell 2008, 135:838-851.
417. Vestergaard P., Baastrup P.C., Petersson H. Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 1977, 56:183-188.
418. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:2837-2842.
419. Vivien D., Ali C. Transforming growth factor-beta signalling in brain disorders. Cytokine Growth Factor Rev 2006, 17:121-128.
420. Volonte C., Ciotti M.T., Merlo D. LiCl promotes survival of GABAergic neurons from cerebellum and cerebral cortex: LiCl induces survival of GABAergic neurons. Neurosci Lett 1994, 172:6-10.
421. Vonsattel J.P., DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998, 57:369-384.
422. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci 2000, 23:20-26.
423. Wang J.F., Azzam J.E., Young L.T. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003, 116:485-489.
424. Wang J.F., Bown C.D., Chen B., Young L.T. Identification of mood stabilizer-regulated genes by differential-display PCR. Int J Neuropsychopharmacol 2001, 4:65-74.
425. Wang J.F., Bown C., Young L.T. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999, 55:521-527.
426. Wang X., Liu P., Zhu H., Xu Y., Ma C., Dai X., et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009, 80:268-273.
427. Wang Y., Mao X.O., Xie L., Banwait S., Marti H.H., Greenberg D.A., et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 2007, 27:304-307.
428. Watase K., Gatchel J.R., Sun Y., Emamian E., Atkinson R., Richman R., et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 2007, 4:e182.
429. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003, 278:25009-25013.
430. Wei H., Leeds P.R., Qian Y., Wei W., Chen R., Chuang D. beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol 2000, 392:117-123.
431. Wei H., Qin Z.H., Senatorov V.V., Wei W., Wang Y., Qian Y., et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001, 106:603-612.
432. Wei H., Wei W., Bredesen D.E., Perry D.C. Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargin-induced depletion of intracellular calcium stores. J Neurochem 1998, 70:2305-2314.
433. Wexler E.M., Geschwind D.H., Palmer T.D. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2008, 13:285-292.
434. White B.C., Sullivan J.M., DeGracia D.J., O'Neil B.J., Neumar R.W., Grossman L.I., et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 2000, 179:1-33.
435. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996, 74:589-607.
436. Whittle B.J., Varga C., Posa A., Molnar A., Collin M., Thiemermann C. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 2006, 147:575-582.
437. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
438. Williams G.O. Management of depression in the elderly. Prim Care 1989, 16:451-474.
439. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417:292-295.
440. Wind T., Hansen M., Jensen J.K., Andreasen P.A. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem 2002, 383:21-36.
441. Woo N.H., Lu B. Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 2006, 12:43-56.
442. Wood N.I., Morton A.J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 2003, 61:375-383.
443. Wyss-Coray T. Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer's. Curr Alzheimer Res 2006, 3:191-195.
444. Xavier I.J., Mercier P.A., McLoughlin C.M., Ali A., Woodgett J.R., Ovsenek N. Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem 2000, 275:29147-29152.
445. Xu J., Culman J., Blume A., Brecht S., Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003, 34:1287-1292.
446. Xu X.H., Hua Y.N., Zhang H.L., Wu J.C., Miao Y.Z., Han R., et al. Greater stress protein expression enhanced by combined prostaglandin A1 and lithium in a rat model of focal ischemia. Acta Pharmacol Sin 2007, 28:1097-1104.
447. Xu J., Scholz A., Rosch N., Blume A., Unger T., Kreutz R., et al. Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. J Hypertens 2005, 23:2277-2285.
448. Xu X.H., Zhang H.L., Han R., Gu Z.L., Qin Z.H. Enhancement of neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia. Brain Res 2006, 1102:154-162.
449. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
450. Yan X.B., Hou H.L., Wu L.M., Liu J., Zhou J.N. Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacology 2007, 53:487-495.
451. Yan X.B., Wang S.S., Hou H.L., Ji R., Zhou J.N. Lithium improves the behavioral disorder in rats subjected to transient global cerebral ischemia. Behav Brain Res 2007, 177:282-289.
452. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major fragileXsyndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.
453. Yang W., Leystra-Lantz C., Strong M.J. Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res 2008, 1196:131-139.
454. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009, 14:51-59.
455. Yenari M.A., Han H.S. Influence of hypothermia on post-ischemic inflammation: role of nuclear factor kappa B (NFkappaB). Neurochem Int 2006, 49:164-169.
456. Yick L.W., So K.F., Cheung P.T., Wu W.T. Lithium chloride reinforces the regeneration-promoting effect of chondroitinase ABC on rubrospinal neurons after spinal cord injury. J Neurotrauma 2004, 21:932-943.
457. Yoshida S., Kirino T., Tamura A., Basugi N., Sano K. Lithium ion does not protect brain against transient ischemia in gerbils. Stroke 1991, 22:84-89.
458. Youdim M.B., Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 2004, 46:1130-1140.
459. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
460. Yu I.T., Kim J.S., Lee S.H., Lee Y.S., Son H. Chronic lithium enhances hippocampal long-term potentiation, but not neurogenesis, in the aged rat dentate gyrus. Biochem Biophys Res Commun 2003, 303:1193-1198.
461. Yu Z., Luo H., Fu W., Mattson M.P. The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Exp Neurol 1999, 155:302-314.
462. Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature 2000, 407:802-809.
463. Yukimasa N., Yoshida K., Ohkushi H., Tanabe S., Fukasawa K., Kanou M., et al. Hepatitis C virus genotyping by restriction fragment length polymorphism of polymerase chain reaction products generated with a HCV detection kit. Rinsho Byori 2001, 49:711-715.
464. Yuskaitis C.J., Mines M.A., King M.K., Sweatt J.D., Miller C.A., Jope R.S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragileXsyndrome. Biochem Pharmacol 2010, 79:632-646.
465. Zarate C.A., Singh J., Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006, 59:1006-1020.
466. Zhang S., Edelmann L., Liu J., Crandall J.E., Morabito M.A. Cdk5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors. J Neurosci 2008, 28:415-424.
467. Zhang Y., Ona V.O., Li M., Drozda M., Dubois-Dauphin M., Przedborski S., et al. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem 2003, 87:1184-1192.
468. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 2003, 278:33067-33077.
469. Zhang H., Vutskits L., Pepper M.S., Kiss J.Z. VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. J Cell Biol 2003, 163:1375-1384.
470. Zhong J., Yang X., Yao W., Lee W. Lithium protects ethanol-induced neuronal apoptosis. Biochem Biophys Res Commun 2006, 350:905-910.
471. Zhou R., Yuan P., Wang Y., Hunsberger J.G., Elkahloun A., Wei Y., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009, 34:1395-1405.
472. Zhuang J., Li F., Liu X., Liu Z., Lin J., Ge Y., et al. Lithium chloride protects retinal neurocytes from nutrient deprivation by promoting DNA non-homologous end-joining. Biochem Biophys Res Commun 2009, 380:650-654.
473. Zoghbi H.Y., Orr H.T. Spinocerebellar ataxia type 1. Semin Cell Biol 1995, 6:29-35.
474. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.